New schizophrenia drug NS-136 enters Mid-Stage trial
Symptom relief
ENROLLING_BY_INVITATION
This study tests a new medicine called NS-136 to see if it can help reduce symptoms of schizophrenia. About 150 adults with acute schizophrenia will receive either a low dose, a high dose, or a placebo pill daily for 5 weeks. Researchers will measure changes in symptom scores and…
Phase: PHASE2 • Sponsor: NeuShen Therapeutics • Aim: Symptom relief
Last updated Apr 26, 2026 19:39 UTC